{
  "title": "Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC",
  "url": "https://www.jacc.org/doi/10.1016/j.jacadv.2025.102204",
  "summary": [
    {
      "type": "bullet",
      "text": "Patient-reported outcomes (PROs) play a crucial role in understanding the full patient experience living with transthyretin amyloid cardiomyopathy (ATTR-CM) and can help improve shared decision-making, treatment escalation, and assessment of treatment response."
    },
    {
      "type": "bullet",
      "text": "In ATTR-CM trials, composite endpoints or \"win\" ratio approaches that include functional endpoints like 6-minute walk distance and PROs like KCCQ are used in combination with traditional cardiovascular outcomes to drive approval by the FDA."
    },
    {
      "type": "bullet",
      "text": "Consistent slowing in the decline of HR-QoL has been observed in recent ATTR-CM trials, indicating the potential of PROs to monitor treatment effects and assess the impact of therapies on disease progression."
    }
  ],
  "model": "granite4:tiny-h"
}